Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes: The MICRO-HOPE Study

Diabetes Care

Volumn 19, Issue 11, 1996, Pages 1225-1228

  Gerstein, Hertzel C ^a,c,d   Bosch, Jackie ^a   Pogue, Janice ^a   Taylor, D Wayne ^a   Zinman, Bernard ^b   Yusuf, Salim ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^d HOPE Project Office   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL;

ADULT; ARTICLE; CAROTID ARTERY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MICROALBUMINURIA; RANDOMIZED CONTROLLED TRIAL; STROKE;

EID: 0029906706     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.19.11.1225     Document Type: Article

References (50)

1. The HOPE Study Investigators: The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol 12:127-137, 1996
2. Deckert T, Kofoed-Enevoldsen A, Norgaard K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen T: Microalbuminuria: implications for micro- and macrovascular disease. Diabetes Can 15:1181-1191, 1992
3. Klein R, Klein BEK, Moss SE: Prevalence of microalbuminuria in older-onset diabetes. Diabetes Care 16:1325-1330, 1993
4. Mattock MB, Morrish NJ, Viberti G, Keen H, Fitzgerald AP, Jackson G: Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 41:736-741, 1992
5. Klein R, Klein BEK, Linton KLP, Moss SE: Microalbuminuria in a population-based study of diabetes. Arch Intern Med 152: 153-158, 1992
6. Coonrod BA, Ellis D, Becker DJ, Bunker CH, Kelsey SF, Lloyd CE, Drash AL, Kuller LH, Orchard TJ: Predictors of microalbuminuria in individuals with IDDM. Diabetes Care 16:1376-1383, 1993
7. Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310:356-360, 1984
8. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118:577-581, 1993
9. Lacourciere Y, Nadeau A, Poirier L, Tancrede G: Captopril or conventional therapy in hypertensive type II diabetics. Hypertension 21:786-794, 1993
10. Mathiesen ER, Hommel E, Giese J, Parving H-H: Efficacy of captopril in postponing nephropathy in normotensive insulin-dependent-diabetic patients with microalbuminuria. BMJ 303:81-87, 1991
11. Viberti GC, Jarrett RJ, Mahmud U, Hill RD, Argyropoulos A, Keen H: Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet i:1430-1432, 1982
12. Mogensen CE, Christensen CK: Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 311:89-93, 1984
13. Humphrey LL, Ballard DJ, Frohnert PP, Chu C-P, O'Fallon M, Palumbo PJ: Chronic renal failure in non-insulin-dependent diabetes mellitus. Ann Intern Med 111:788-796, 1989
14. Fabre J, Balant LP, Dayer PG, Fox HM, Vernet AT: The kidney in maturity onset diabetes mellitus: a clinical study of 510 patients. Kidney Int 21:730-738, 1982
15. Borch-Johnsen K, Andersen PK, Deckert T: The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 28:590-596, 1985
16. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
17. Noth RH, Krolewski AS, Kaysen GA, Meyer TW, Schambelan M: Diabetic nephropathy, hemodynamic basis and implications for disease management. Ann Intern Med 110:795-813, 1989
18. Krowlewski AS, Warren JH, Christlieb AR, Busick EJ, Kahn CR: The changing natural history of nephropathy in type 1 diabetes. Am J Med 78:785-794, 1985
19. Viberti G: Etiology and prognostic significance of albuminuria in diabetes. Diabetes Care 11:84-845, 1988
20. Viberti G, Yip-Messent J, Morocutti A: Diabetic nephropathy: future avenue. Diabetes Care 15:1216-1225, 1992
21. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE: Microalbuminuria as predictor of increased mortality in elderly people. BMJ 300:297-300, 1990
22. Haffner SM, Stern MP, Gruber MKK, Hazuda HP, Mitchell BD, Patterson JK: Microalbuminuria. Potential marker for increased cardiovascular risk factors in nondiabetic subjects? Arteriosclerosis 10:727-731, 1990
23. Neil A, Hawkins M, Potok M, Thorogood M, Cohen D, Mann J: A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care 16:996-1003, 1993
24. Schmitz A, Vaeth M: Microalbuminuria: a major risk factor in non-insulin-dependent diabetes: a 10-year follow-up study of 503 patients. Diabetic Med 5:126-134, 1988
25. Stehouwer CDA, Nauta JJP, Zeldenrust GC, Hackeng WHL, Donker AJM, Den Ottolander GJH: Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 340:319-323, 1992
26. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE: Eight to nine year mortality in known non-insulin dependent diabetes and controls. Kidney Int 42:731-735, 1992
27. Messent JWC, Elliott TG, Hill RD, Jarrett RJ, Keen H, Viberti G: Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study. Kidney Int 41:836-839, 1992
28. Niskanen L, Uusitupa M, Sarlund H, Siitonen O, Voutilanen E, Penttila I, Pyorala K: Microalbuminuria predicts the development of serum lipoprotein abnormalities favoring atherogenesis in newly diagnosed type 2 (non-insulin-dependent) diabetic patients. Diabetologia 33:237-243, 1990
29. Yudkin JS: Microalbuminuna: a genetic link between diabetes and cardiovascular disease. Ann Med 24:517-522, 1992
30. Weidmann P, Boehlen LM, de Courten M, Ferrari P: Antihypertensive therapy in diabetic patients. J Hum Hypertens 6 (Suppl. 2):23-36, 1992
31. Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF: Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 118:129-138, 1993
32. Parving H, Gall M, Skott P, Jorgensne HE, Lokkegaard H, Jorgensen F, Nielsen B, Larsen S: Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int 41:758-762, 1992
33. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B: Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 90:2056-2069, 1994
34. Keane WF, Shapiro BE: Renal protective effect of angiotensin-converting enzyme inhibition. Am J Cardiol 65:491-531, 1990
35. Savage S, Schrier RW: Progressive renal insufficiency: The role of angiotensin converting enzyme inhibitors. Adv Int Med 37:85-101, 1991
36. Lever AF: Angiotensin II, angiotensin-converting enzyme inhibitors and blood vessel structure. Am J Med 92 (Suppl. 4B):35S-38S, 1992
37. Luscher TF: Angiotensin, ACE inhibitors and endothelial control of vasomotor tone. Basic Res Cardiol 88 (Suppl. 1):15-24, 1993
38. Donnelly R: Angiotensin-converting enzyme inhibitors and insulin sensitivity: metabolic effects in hypertension, diabetes and heart failure. J Cardiovasc Pharm 20 (Suppl. 11):S38-S44, 1992
39. Gisinger C, Watanabe J, Colwell JA: Vitarain E and platelet eicosanoids in diabetes mellitus. Prostaglandins Leukot Essent Fatty Adds 40:169-176, 1990
40. Paolisso G, D'Amore A, Giugliano D, Ceriello A, Varricchio M, D'onofrio F: Pharmacologic doses of vitamin E improve insulin action in healthy subjects and non-insulin dependent diabetic patients. Am J Clin Nutr 57:650-656, 1993
41. Paolisso G, D'Amore A, Galzerano G, Balbi V, Giugliano D, Varricchio M, D'onofrio F: Daily vitamin E supplements improve metabolic control but not insulin secretion in elderly type II diabetic patients. Diabetes Care 16:1433-1437, 1993
42. Ceriello A, Giugliano D, Quatraro A, Donzella C, Dipalo G, Lefebvre PJ: Vitamin E reduction of protein glycosylation in diabetes. Diabetes Care 14:68-72, 1991
43. Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Torella R: A preliminary note on inhibiting effect of a-tocopherol (vit. E) on protein glycation. Diabetic Metab 14:40-42, 1988
44. Jha P, Flather M, Lonn E, Farkouh M, Yusuf S: The antioxidant vitamins (E, C and carotenes) and cardiovascular disease: a critical summary of epidemiologic and clinical trial data. Ann Intern Med 123:860-872, 1995
45. Ellis D, Coonrod BA, Dorman JS, Kelsey SF, Becker DJ, Avner ED, Orchard TJ: Choice of urine sample predictive of microalbuminuria in patients with insulin-dependent diabetes mellitus. Am J Kidney Dis 13:321-328, 1989
46. Gatling W, Knight C, Hill RD: Screening for early diabetic nephropathy: which sample to detect microalbuminuria. Diabetic Med 2:451-455, 1985
47. Marshall SM: Screening for microalbuminuria: which measurement? Diabetic Med 8:706-711, 1991
48. Gatling W, Knight C, Mullee MA, Hill RD: Microalbuminuria and diabetes: a population study of the prevalence and an assessment of three screening tests. Diabetic Med 5:343-347, 1988
49. Harrison NA, Rainford DJ, White GA, Cullen SA, Strike PW: Proteinuria: what value is the dipstick? Br J Urol 63:202-208, 1989
50. Meinert CL, Tonascio S: Sample size and power estimates. In Clinical Trials: Design, Conduct and Analysis. New York, Oxford University Press, 1986, p. 71-89